Long-term disease control and safety with the anti-CCR4 antibody mogamulizumab: Post-hoc analyses from the MAVORIC trial of patients with previously treated cutaneous T-cell lymphoma

DERMATOLOGIC THERAPY

WILEY

1. Kyowa Kirin, Inc.